Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

Completed · Phase 2 · Has a placebo group

Conditions studied: Lewy Body Dementia, Visual Hallucinations

In brief

This study seeks to evaluate safety and efficacy of Nelotanserin for the treatment of visual hallucinations in subjects with Lewy body dementia.

Key facts

Study ID

NCT02640729

Run by

Axovant Sciences Ltd.

People needed

30

Starts

2015-12-01

Expected to finish

2017-11-01

Last updated by the study team

2018-01-18

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult subjects at least 50 years of age, with a diagnosis of LBD based on DSM-5 diagnostic criteria or diagnosis of Parkinson's disease dementia (PDD) based on DSM-5 diagnostic criteria;
• Presence of frequent visual hallucinations
• Mini Mental State Examination score ≥ 18

You may not qualify if…

• Subjects have a current diagnosis of significant psychotic disorders including, but not limited to, schizophrenia or bipolar disorder
• Subjects' psychotic symptoms are secondary to or better accounted for by another medical condition, psychiatric disorder, or substance abuse
• Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder

Where it is running

• US123 — Fountain Valley, California, United States
• US114 — Boca Raton, Florida, United States
• US113 — Orlando, Florida, United States
• US132 — Lenexa, Kansas, United States
• US103 — Rochester, Minnesota, United States
• US129 — Lincoln, Nebraska, United States
• US101 — Chapel Hill, North Carolina, United States
• US104 — Cleveland, Ohio, United States
• US105 — Columbus, Ohio, United States
• US131 — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.